Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
44.72
+0.60 (1.36%)
May 4, 2026, 11:49 AM EDT - Market open
Travere Therapeutics Revenue
In the year 2025, Travere Therapeutics had annual revenue of $490.73M with 110.45% growth. Travere Therapeutics had revenue of $129.69M in the quarter ending December 31, 2025, with 73.41% growth.
Revenue (ttm)
$490.73M
Revenue Growth
+110.46%
P/S Ratio
8.46
Revenue / Employee
$987,380
Employees
497
Market Cap
4.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 490.73M | 257.55M | 110.45% |
| Dec 31, 2024 | 233.18M | 87.94M | 60.55% |
| Dec 31, 2023 | 145.24M | 35.78M | 32.69% |
| Dec 31, 2022 | 109.46M | -22.38M | -16.97% |
| Dec 31, 2021 | 131.84M | -66.49M | -33.52% |
| Dec 31, 2020 | 198.32M | 22.98M | 13.11% |
| Dec 31, 2019 | 175.34M | 11.09M | 6.75% |
| Dec 31, 2018 | 164.25M | 9.31M | 6.01% |
| Dec 31, 2017 | 154.94M | 21.35M | 15.98% |
| Dec 31, 2016 | 133.59M | 33.70M | 33.74% |
| Dec 31, 2015 | 99.89M | 71.69M | 254.19% |
| Dec 31, 2014 | 28.20M | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.07B |
| Legend Biotech | 1.03B |
| Telix Pharmaceuticals | 803.79M |
| Catalyst Pharmaceuticals | 588.99M |
| Ligand Pharmaceuticals | 268.09M |
| Crinetics Pharmaceuticals | 7.70M |
| CRISPR Therapeutics AG | 3.51M |
| Dianthus Therapeutics | 2.04M |
TVTX News
- 6 days ago - Travere Therapeutics to Report First Quarter 2026 Financial Results - Business Wire
- 19 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 20 days ago - FDA Approval For Travere's Drug Expands Reach To Broader Rare Kidney Disease Patients - Benzinga
- 20 days ago - Travere Therapeutics Transcript: Study update - Transcripts
- 20 days ago - US FDA expands approval for Travere Therapeutics' drug for rare kidney disease - Reuters
- 20 days ago - Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS - Business Wire
- 2 months ago - Travere Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire